NOTRELOAD AI
  • NOTRELOAD AI
  • Stocks BUZZ.
  • #TrumpTrade
  • 24-HOUR Pass →
  • Invest ↗
Sign in Subscribe

Wall Street Starts Coverage on PLSE and ENGN: What You Need to Know

Mizuho and Jefferies initiate coverage on Pulse Biosciences and enGene, highlighting growth potential, strong clinical data, and upcoming catalysts in biotech.

Wall Street Starts Coverage on PLSE and ENGN: What You Need to Know
Credit: Pulse Biosciences
Already have an account? Sign in.
01/30/2026 · 9:54 AM
ENGN
/ Don't stop with just one post.

Related↓

enGene Upgraded to Strong Buy on Promising Bladder Cancer Data
11/11/2025 · 9:46 AM

enGene Upgraded to Strong Buy on Promising Bladder Cancer Data

Raymond James upgrades enGene to Strong Buy with $27 target as detalimogene shows 62% complete response rate in bladder cancer trial with excellent tolerability.

/ Subscriber only
/ Read more

Feed↓

FDA Cracks Down on Compounded GLP-1 Weight Loss Drugs
Featured/ 02/06/2026 · 5:34 PM

FDA Cracks Down on Compounded GLP-1 Weight Loss Drugs

FDA plans to restrict non-approved compounded GLP-1 drugs sold by Hims & Hers and compounding pharmacies, citing safety concerns and misleading marketing practices.

/ Subscriber only
DraftKings Teams Up With Crypto.com for Expanded Prediction Markets
02/06/2026 · 4:05 PM

DraftKings Teams Up With Crypto.com for Expanded Prediction Markets

DraftKings (DKNG) partners with Crypto.com to expand prediction markets, adding player-specific sports contracts and new categories including politics and entertainment.

/ Subscriber only
Pfizer’s Chantix Move Seen as Positive Signal for Achieve Life Sciences
02/06/2026 · 3:53 PM

Pfizer’s Chantix Move Seen as Positive Signal for Achieve Life Sciences

Analysts say Pfizer listing Chantix on TrumpRx may support Achieve Life Sciences and boost confidence in cytisinicline’s approval prospects.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe